Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years

A Phase II, Randomized, Controlled, Observer-blind, Single-center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of an H5N1 Influenza Vaccine in Subjects Aged 6 Months to 17 Years

Evaluate the immune response and reactogenicity of H5N1 vaccination in subjects aged 6 months to 17 years compared to seasonal flu vaccination

Inclusion Criteria:

• Healthy subjects

Exclusion Criteria:

• Receipt of Seasonal Influenza Vaccine for season 2007/2008
• Receipt of another vaccine within 3 weeks before and after each vaccination
• Previous vaccination with a pandemic candidate vaccine and/or vaccine containing the adjuvant MF59 or a similar adjuvant
• Children who are in the local recommendation for influenza vaccination due to underlying diseases